Investors

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient´s dendritic cells to activate an immune response specific to the patient´s disease. Argos´ most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV.


Stock Quote

NASDAQ: ARGS
0.14
- 0.02 (-14.17%)

Day High:
0.17

Day Low:
0.13

Volume:
6,125,290

4:00 PM ET on Jan 16, 2018
Delayed at least 20 minutes.